Skip to main content
RPID
NASDAQ Industrial Applications And Services

Rapid Micro Q2 Revenue Climbs 11%, Gross Margin Reaches 15%, but Cash Burn Accelerates; Workforce Cuts Announced

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.08
Mkt Cap
$103.629M
52W Low
$1.66
52W High
$4.94
52W Position info
25% above low
Off High info
58% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

RPID sits 25% above its 52-week low of $1.66.

Summary

Rapid Micro Biosystems posted 11% revenue growth and a record 15% gross margin in Q2 2026, but cash burn accelerated and cash reserves fell to $14.7 million. A post-quarter workforce reduction aims to save $3 million in 2027, while the CEO adopted a new 10b5-1 plan to sell up to 396,828 shares.


Key Events · Earnings and Guidance · RPID

  • Q2 Revenue Up 11%, Gross Margin Improves

    Revenue reached $8.1 million, driven by higher consumable sales and system placements. Gross margin expanded to 15.0% from 3.8% a year ago, reflecting lower service costs and improved product margins.

  • Net Loss Widens, Cash Burn Accelerates

    Net loss was $12.9 million vs. $11.9 million in Q2 2025. Operating cash outflow was $27.8 million in H1 2026, up from $18.8 million a year earlier, driven by working capital changes and higher personnel costs.

  • Cash Reserves Dwindle to $14.7 Million

    Cash and equivalents fell to $14.7 million from $20.0 million at year-end 2025, despite $9.6 million in financing proceeds from the May 2026 offering. The company expects existing resources plus potential debt tranches to fund operations for at least 12 months.

  • Post-Quarter Workforce Reduction Announced

    In August 2026, the company implemented cost actions including workforce reductions, expecting to save approximately $3 million in 2027 and $1 million in the remainder of 2026, with a $0.4 million charge in Q3 2026.


Analysis · RPID · Industrial Applications And Services

Rapid Micro Biosystems delivered Q2 2026 revenue of $8.1 million, an 11% year-over-year increase, while gross margin jumped to 15% from 3.8% a year ago. Yet the net loss widened to $12.9 million, and cash used in operations surged to $27.8 million in the first half, leaving just $14.7 million in cash and equivalents. In a post-quarter move signaling urgent cost control, the company disclosed a workforce reduction expected to save roughly $3 million in 2027. Adding potential selling pressure, the CEO adopted a new 10b5-1 trading plan for up to 396,828 shares. Despite improving gross margins, the combination of accelerating cash burn, a shrinking cash cushion, and a restructuring underscores the company's fragile financial position.

At the time of this filing, RPID was trading at $2.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $103.6M. The 52-week trading range was $1.66 to $4.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RPID - Latest Insights

RPID
Aug 07, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.08
Real-time Price: $2.08 info
Change: $0 (0%) info
Market Cap: $103.629M info
RPID
May 19, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $2.08 info
Change: +$0.100 (+5%) info
Market Cap: $103.629M info
RPID
May 19, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $2.08 info
Change: +$0.100 (+5%) info
Market Cap: $103.629M info
RPID
May 19, 2026, 5:12 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $2.08 info
Change: +$0.100 (+5%) info
Market Cap: $103.629M info
RPID
May 19, 2026, 5:10 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $2.08 info
Change: +$0.180 (+9%) info
Market Cap: $103.629M info